JointHealth™ express December 9, 2013
Health Canada approves adalimumab for ulcerative colitis
Health Canada recently approved adalimumab (Humira®) to treat adults with moderate to severe ulcerative colitis (UC) who are unresponsive to conventional therapy.
Adalimumab is currently approved in Canada for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), and psoriasis (Ps) in adults. Adalimumab has also been approved to treat polyarticular juvenile idiopathic arthritis (pJIA) in children aged 4 to 17 years and Crohn’s disease in children aged 13 to 17 years.
Ulcerative colitis is a chronic disease of the colon, marked by inflammation and ulceration of the innermost lining of the colon. Approximately 104,000 people in Canada live with UC. The symptoms of ulcerative colitis have a strong association with seronegative spondyloarthropathies, which include PsA and AS.
Canadians who have been prescribed adalimumab will be offered an opportunity to enroll in a patient support program called PROGRESS—a program that provides services including insurance, injection, education, and ongoing support.
In a press release published in the Wall Street Journal, Dr. Kevin Glasgow, Chief Executive Officer of the Crohn’s and Colitis Foundation of Canada, said, “The Crohn’s and Colitis Foundation of Canada is committed to finding cures for ulcerative colitis and Crohn’s disease. While we work on finding cures, we are committed to improving the lives of children and adults affected by inflammatory bowel disease (IBD). IBD treatments approved by Health Canada will increase access, provide more treatment options, and improve the quality of life of Canadians living with ulcerative colitis.”
To learn more about adalimumab, please click here.
Health Canada approves adalimumab for ulcerative colitis
Health Canada recently approved adalimumab (Humira®) to treat adults with moderate to severe ulcerative colitis (UC) who are unresponsive to conventional therapy.
Adalimumab is currently approved in Canada for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), and psoriasis (Ps) in adults. Adalimumab has also been approved to treat polyarticular juvenile idiopathic arthritis (pJIA) in children aged 4 to 17 years and Crohn’s disease in children aged 13 to 17 years.
Ulcerative colitis is a chronic disease of the colon, marked by inflammation and ulceration of the innermost lining of the colon. Approximately 104,000 people in Canada live with UC. The symptoms of ulcerative colitis have a strong association with seronegative spondyloarthropathies, which include PsA and AS.
Canadians who have been prescribed adalimumab will be offered an opportunity to enroll in a patient support program called PROGRESS—a program that provides services including insurance, injection, education, and ongoing support.
In a press release published in the Wall Street Journal, Dr. Kevin Glasgow, Chief Executive Officer of the Crohn’s and Colitis Foundation of Canada, said, “The Crohn’s and Colitis Foundation of Canada is committed to finding cures for ulcerative colitis and Crohn’s disease. While we work on finding cures, we are committed to improving the lives of children and adults affected by inflammatory bowel disease (IBD). IBD treatments approved by Health Canada will increase access, provide more treatment options, and improve the quality of life of Canadians living with ulcerative colitis.”
To learn more about adalimumab, please click here.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.